The FDA approved AstraZeneca’s baxdrostat for certain patients with hypertension, according to the company. Baxdrostat is intended to address elevated aldosterone pathways, giving physicians another option within treatment algorithms for patients who meet approved criteria. The approval matters for payers and prescribing decisions because label coverage and real-world sequencing of therapies will likely determine uptake. AstraZeneca’s commercialization plans will also hinge on how quickly clinicians adopt the drug relative to existing standard-of-care and competing agents. The company framed the approval as part of its growth roadmap targeting major revenue milestones, placing baxdrostat into a more competitive hypertension segment.